Does one guideline fit all?

Neurology

Volumn 77, Issue 24, 2011, Pages 2080-2081

  Richert, Nancy D ^a   Kryscio, Richard J ^b  

^a BIOGEN   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

CLINICAL TRIAL (TOPIC); CONTRAST ENHANCED LESION; EDITORIAL; EVIDENCE BASED PRACTICE; EXPANDED DISABILITY STATUS SCALE; HUMAN; LESIONS AND DEFECTS; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SAFETY; POST HOC ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; RELAPSE; RISK REDUCTION; SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS; SENSITIVITY AND SPECIFICITY; THERAPY EFFECT; TREATMENT FAILURE;

EID: 84856147128     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31823d76ba     Document Type: Editorial

References (10)

1. Miller DH. Guidelines for MRI monitoring of the treatment of multiple sclerosis: recommendations of the US Multiple Sclerosis Society's task force. Mult Scler 1996;1:335-338. (Pubitemid 126701293)
2. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992;32:758-766.
3. Bielekova B, Goodwin B, Richert N, et al. Encephalitic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000;6:1167-1175.
4. Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis: Gadolinium MRI Meta-analysis Group. Lancet 1999;353:964-969. (Pubitemid 29132605)
5. Sormani MP, Bonzano L, Roccatagliata L, et al. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol 2009;65:268-275.
6. Sormani MP, Bonzano L, Roccatagliata L, et al. Surrogate endpoints for EDSS worsening in multiple sclerosis. Neurology 2010;75:302-309.
7. Riddell CA, Zhao Y, Li D K B, et al. Evaluation of safety monitoring guidelines based on MRI lesion activity in multiple sclerosis. Neurology 2011;77:2089-2096.
8. The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999;53:457-465.
9. Zhao Y, Petkau AJ, Traboulsee A, Riddehough A, Li DK. Does MRI lesion activity regress in secondary progressive multiple sclerosis? Mult Scler 2010;16:434-442.
10. Barkhof F, Held U, Simon JH, et al. Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials. Neurology 2005;65:1447-1454. (Pubitemid 41552778)